Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices.
But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
Healthcare diagnostics company Labcorp Holdings (NYSE:LH) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 8.6% year on year to $3.56 billion. Its non-GAAP profit of $4.18 per share was 1% above analysts’ consensus estimates.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Tuesday as we examine the latest happenings in today's session.
Shares of healthcare diagnostics company Labcorp Holdings (NYSE:LH)
fell 3.8% in the morning session after the company's third-quarter results, while beating headline estimates, revealed a miss on a key profitability metric and included guidance that failed to impress investors. The healthcare diagnostics company reported revenue of $3.56 billion, in line with Wall Street expectations, and an adjusted profit of $4.18 per share, which was 1% above consensus. However, investors looked past the top- and bottom-line beats to focus on other details. The company's adjusted EBITDA of $596.8 million missed analyst estimates. Furthermore, while Labcorp slightly raised its full-year adjusted earnings per share guidance, the modest revision appeared to underwhelm the market, which was likely anticipating a more robust outlook.
Healthcare diagnostics company Labcorp Holdings (NYSE:LH) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 8.6% year on year to $3.56 billion. Its non-GAAP profit of $4.18 per share was 1% above analysts’ consensus estimates.
While profitability is essential, it doesn’t guarantee long-term success.
Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".
Generating cash is essential for any business, but not all cash-rich companies are great investments.
Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry’s 13.9% return has trailed the S&P 500 by 18.8 percentage points.
bioAffinity Technologies, Inc. (NASDAQ: BIAF) has emerged as a standout performer in the financial markets today, September 26, 2025, with its stock experiencing a dramatic surge. The significant uptick, which saw shares climb by over 52% in premarket trading and reach highs of 79% and 60.71% during Friday's session,
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities.
However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Labcorp (NYSE:LH) and the rest of the testing & diagnostics services stocks fared in Q2.
